Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
By E. Weisberg, Christina L. Boulton, Louise M. Kelly, P. Manley, D. Fabbro, T. Meyer, D. Gilliland, James D. Griffin. Cancer Cell, 2002
636 citations recorded by the source corpus.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/c8823a5ff96e7b27e4349dc30cc9ee2a20a2b0fd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “Median d from diagnosis to trial entry (range) 21 (6-166)”
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. (2003, background): “Recent evidence in mouse models suggests that FLT3-ITD mutations alone induce myeloproliferative disease, whereas additional mutations are needed to induce AML.15,16 In addition to SU11248, several other small-molecule FLT3 inhibitors have been recently described, including AG1295,39 PKC412,40 CT535”
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005, neutral): “Median platelet count, 1000/ L (range) 30 (1-619)”
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017, background): “A classification of favorable indicated the presence of t(8;21) and inv(16) or t(16;16), normal the presence of a normal karyotype, intermediate II the presence of cytogenetic abnormalities that were not classified as favorable or adverse, and adverse the presence of adverse-risk cytogenetic abnorma”
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. (2003, neutral): “Characteristic N = 22 Median (range) Age 66 (22-80) WBC (x109/L) 2.”